3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Neoplasms
3
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Lymphoma, Large-Cell, Anaplastic
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms by Histologic Type
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
Magnetic Resonance Spectroscopy
3
Everolimus
3
atezolizumab
2
Nivolumab
2
Fluorodeoxyglucose F18
2
FAPI-46
2
tivozanib
1
romidepsin
1
pembrolizumab
1
pasireotide
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
exemestane
1
entrectinib
1
cabozantinib
1
alectinib
1
Specimen Handling
1
Respiratory Therapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
PT-100 dipeptide
1
Neuropsychological Tests
1
Molecular Diagnostic Techniques
1
Lenalidomide
1
Lactones
1
LY2584702
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
alectinib
×
Genitourinary
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts